Expanding the Clinical Lens for GLP‑1 Therapy

The Role of Liver Elastography and DEXA‑Based Body Composition

As GLP‑1 therapies continue to reshape metabolic care, the need for more precise clinical assessment has become increasingly apparent. Traditional reliance on body mass index (BMI) often oversimplifies disease severity and overlooks clinically relevant risk factors. 

Liver elastography and DEXA-based body composition analysis expand the clinical lens by offering objective measures of liver health and visceral adiposity, enabling more nuanced evaluation and documentation to support appropriate GLP‑1 treatment.

Key Takeaways

• BMI alone incompletely reflects metabolic risk, often obscuring visceral adiposity and liver disease relevant to GLP‑1 therapy decisions.
• Liver elastography provides noninvasive insight into liver fat and fibrosis – key markers of risk not captured by weight-based metrics.
• DEXA-based body composition analysis objectively quantifies visceral fat, total adiposity and lean mass distribution beyond BMI.
• Advanced imaging helps clarify disease burden in patients with borderline BMI or metabolic comorbidities.
• Incorporating liver elastography and DEXA supports more precise clinical assessment, documentation and individualized GLP‑1 care.

Why BMI Alone Falls Short

BMI remains a common screening tool for obesity. However, it offers a limited and often misleading view of metabolic health. BMI does not distinguish between adipose tissue and lean mass, nor does it capture fat distribution – particularly visceral adiposity.  Liver fat, an important component of visceral fat, is strongly associated with insulin resistance, heart disease and liver pathology. 

Patients with similar BMIs may have markedly different metabolic risk profiles. As a result, reliance on BMI alone can underestimate disease burden and obscure clinical need. 

Beyond BMI: Liver Elastography and DEXA Insights

Liver elastography and DEXA-based body composition analysis provides clinicians with a more nuanced assessment of adiposity, organ-specific risk and treatment justification for GLP‑1 therapy. 

Liver elastography offers a noninvasive way to evaluate liver health and metabolic risk by assessing: 

• Hepatic stiffness 
• Liver adiposity 
• Fibrosis risk 
• Metabolic disease stratification

DEXA-based body composition analysis complements liver elastography insights by providing objective data on adiposity patterns, such as: 

• Total body fat
• Visceral adipose tissue
• Lean mass distribution
• Fat distribution 

Together, these tools help clarify disease burden, differentiate obesity phenotypes and document clinically relevant risk. For clinicians evaluating the appropriateness of GLP‑1 therapy, advanced imaging can support more informed clinical decision-making and strengthen the rationale for treatment beyond generalized weight measures.

When to Consider Liver Elastography and DEXA in GLP‑1 Care

Liver elastography and DEXA-based body composition analysis may be appropriate when standard metrics fail to fully capture a patient’s metabolic risk or disease burden. Clinicians may consider these advanced imaging tests for the following situations:

• Borderline BMI values
• Suspected visceral adiposity
• Metabolic comorbid conditions
• Nonalcoholic fatty liver disease (NAFLD) risk indicators
• GLP‑1 documentation needs

By providing objective, organ- and tissue‑specific data, advanced imaging helps PCPs make more informed treatment decisions and better individualize GLP‑1 care.

Precision Assessment for GLP‑1 Clinical Decision‑Making

As GLP‑1 therapy continues to evolve, relying on BMI alone may limit appropriate patient identification and treatment planning. Incorporating liver elastography and DEXA-based body composition supports precise assessment, documentation and individualized GLP‑1 care beyond weight-centric measures.

Resources

“The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.” NIH: National Library of Medicine, 2023. 

Physician Outreach and Connections

Our growth and outreach liaisons provide support and information to referring physicians and other healthcare providers.